Charles River Laboratories Reports Strong Q2 2025 Results and Updates Guidance

Details

reported its Q2 2025 financial results on August 6, 2025, with non-GAAP earnings per share of $3.12, surpassing the market expectation of $2.80 per share. The company also updated its 2025 guidance to reflect better-than-expected second-quarter financial results. Additionally, the U.S. Department of Justice investigation into the NHP supply chain was resolved, with shipments from late 2022 and early 2023 cleared for legal entry into the United States.

Items reported

Exhibits (1)

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.